2.4.2.12: nicotinamide phosphoribosyltransferase
This is an abbreviated version!
For detailed information about nicotinamide phosphoribosyltransferase, go to the full flat file.
Word Map on EC 2.4.2.12
-
2.4.2.12
-
adipokines
-
adiponectin
-
leptin
-
obesity
-
adipose
-
resistin
-
adipocytokines
-
nad+
-
obese
-
women
-
adipocytes
-
mellitus
-
cardiovascular
-
visceral
-
necrosis
-
salvage
-
cholesterol
-
sirt1
-
endothelial
-
tnf
-
homa-ir
-
triglyceride
-
apelin
-
sirtuins
-
atherosclerosis
-
c-reactive
-
chemerin
-
interleukin-6
-
anthropometric
-
insulin-mimetic
-
ghrelin
-
circumference
-
overweight
-
lean
-
omentin
-
polycystic
-
adiposity
-
waist
-
vaspin
-
pai-1
-
hs-crp
-
c-peptide
-
obesity-related
-
protein-4
-
retinol-binding
-
adipsin
-
normal-weight
-
index-matched
-
pharmacology
-
irisin
-
medicine
-
nmnats
-
drug development
- 2.4.2.12
- adipokines
- adiponectin
- leptin
- obesity
- adipose
-
resistin
-
adipocytokines
- nad+
-
obese
- women
- adipocytes
- mellitus
- cardiovascular
- visceral
- necrosis
-
salvage
- cholesterol
- sirt1
- endothelial
- tnf
-
homa-ir
- triglyceride
- apelin
- sirtuins
- atherosclerosis
-
c-reactive
- chemerin
- interleukin-6
-
anthropometric
-
insulin-mimetic
- ghrelin
-
circumference
- overweight
-
lean
-
omentin
-
polycystic
-
adiposity
-
waist
- vaspin
- pai-1
-
hs-crp
- c-peptide
-
obesity-related
- protein-4
-
retinol-binding
- adipsin
-
normal-weight
-
index-matched
- pharmacology
-
irisin
- medicine
- nmnats
- drug development
Reaction
Synonyms
eNAMPT, extracellular nicotinamide phosphoribosyltrasferase, iNAMPT, Nam phosphoribosyltransferase, NAmPRTase, Nampt, Nampt/PBEF/Visfatin, Nampt/visfatin, NAMPTA, NAMPTB, NAPRT, nicotinamide mononucleotide pyrophosphorylase, nicotinamide mononucleotide synthetase, nicotinamide phosphoribosyl transferase, nicotinamide phosphoribosyltransferase, nicotinamide phosphoribosyltransferase/Visfatin, NMN pyrophosphorylase, NMN synthetase, NMPRTase, PBEF, phosphoribosyltransferase, nicotinamide, pre-B cell colony enhancing factor, pre-B cell colony enhancing factor(PBEF), pre-B cell colony-enhancing factor, pre-B cell colony-enhancing factor (PBEF), pre-B cell colony-enhancing factor 1, pre-B colony enhancing factor, pre-B-cell colony enhancing factor, pre-B-cell colony-enhancing factor, Visfatin
ECTree
2.4.2.12 nicotinamide phosphoribosyltransferaseAdvanced search results
results (
results (Inhibitors
Inhibitors on EC 2.4.2.12 - nicotinamide phosphoribosyltransferase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
INHIBITOR 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
(2E)-1-(4-[[2-(4-fluorophenyl)-1,3-thiazol-4-yl]methyl]piperazin-1-yl)-3-(pyridin-3-yl)prop-2-en-1-one
-
(2E)-3-(6-aminopyridin-3-yl)-N-((5-[4-(4,4-difluoropiperidine-1-carbonyl)phenyl]-7-(4-fluorophenyl)-1-benzofuran-2-yl)methyl)prop-2-enamide
(2E)-3-(pyridin-3-yl)-1-[4-[4-(trifluoromethoxy)benzyl]piperazin-1-yl]prop-2-en-1-one
-
(2E)-3-(pyridin-3-yl)-N-[4-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)phenyl]prop-2-enamide
-
(2E)-3-(pyridin-3-yl)-N-[6-(3-[[4-(trifluoromethyl)phenyl]sulfamoyl]phenyl)hexyl]prop-2-enamide
-
(2E)-N-(6-[3-[(2,5-dimethylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(2-methylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
most potent inhibitor
(2E)-N-(6-[3-[(3-chloro-4-fluorophenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(3-methylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-chlorophenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-ethylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-fluorophenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-methylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-phenoxyphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-tert-butylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[2-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-6-yl)oxy]ethyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[3-[3-(phenylsulfamoyl)phenyl]propyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[3-[4-(phenylsulfamoyl)phenyl]propyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[4-[4-(phenylsulfamoyl)phenyl]butyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[5-[3-(phenylsulfamoyl)phenyl]pentyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[5-[4-(phenylsulfamoyl)phenyl]pentyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[5-[4-([[2-(1H-indol-3-yl)ethyl](propan-2-yl)amino]methyl)anilino]pentyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[6-[3-(phenylsulfamoyl)phenyl]hexyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[6-[4-(phenylsulfamoyl)phenyl]hexyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[7-[3-(phenylsulfamoyl)phenyl]heptyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[7-[4-(phenylsulfamoyl)phenyl]heptyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2R,2'R)-5,5',7,7'-tetrahydroxy-2,2'-bis(4-hydroxyphenyl)-2,2',3,3'-tetrahydro-4H,4'H-[3,8'-bi-1-benzopyran]-4,4'-dione
-
-
(3R,5R,7R)-N-(4-((E)-3-(pyridin-3-yl)acrylamido)butyl)adamantane-1-carboxamide
-
(E)-N-(4-(1,12-dicarba-closo-dodecaboranyl)amidebutyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(1,12-dicarba-closo-dodecaboranyl)amidepentyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(1,7-dicarba-closo-dodecaboranyl)amidebutyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(1-(1,12-dicarba-closo-dodecaboranyl)piperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(1-benzoyl-1,12-dicarba-closo-dodecaboran-12-yl)amidebutyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(1-trimethylsilyl-1,12-dicarba-closododecaboran-12-yl)amidebutyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(4-(1,12-dicarba-closo-dodecaboranecarbonyl)-1,12-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(4-(1,12-dicarba-closo-dodecaboranecarbonyl)-1,7-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(4-(1,12-dicarba-closo-dodecaboranyl(hydroxy)methyl)-1,12-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(4-(1,7-dicarba-closo-dodecaboranecarbonyl)-1,12-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
-
1,1-dioxo-N-[[4-[(4-pyrrolidin-1-yl-1-piperidyl)sulfonyl]-phenyl]methyl]-2H-pyrido[4,3-e][1,2,4]thiadiazin-3-amine
-
1-((E)-4-(3-(pyridin-3-yl)acrylamido)hexyl)-1,12-dicarba-closo-dodecaborane
-
1-((E)-4-(3-(pyridin-3-yl)acrylamido)hexyl)-1,2-dicarba-closo-dodecaborane
-
1-((E)-4-(3-(pyridin-3-yl)acrylamido)pentyl)-1,2-dicarba-closo-dodecaborane
-
1-(4-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)butyl)-1,2-dicarba-closo-dodecaborane
-
1-(4-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)pentyl)-1,2-dicarba-closo-dodecaborane
-
1-(5-(1H-pyrrolo[3,2-c]pyridine-2-carboxamido)butyl)-1,2-dicarba-closo-dodecaborane
-
1-(5-(1H-pyrrolo[3,2-c]pyridine-2-carboxamido)pentyl)-1,2-dicarba-closo-dodecaborane
-
1-([1,1'-biphenyl]-2-yl)-3-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)urea
-
1-methyl-N-[4-(phenylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
1-[3-(piperidin-1-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)thiourea
-
potent inhibitor
1-[4-(8-oxa-3-azabicyclo[3.2.1]oct-3-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
-
1-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-3-(pyridin-3-ylmethyl)thiourea
-
-
1H-indol-2-yl(4-[[3-(pyridin-3-yl)-1H-pyrazol-5-yl]carbonyl]piperazin-1-yl)methanone
-
2'-([7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]carbamoyl)[1,1'-biphenyl]-2-carboxylic acid
-
2'-([7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]carbamoyl)[1,1'-biphenyl]-3-carboxylic acid
-
2'-([7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]carbamoyl)[1,1'-biphenyl]-4-carboxylic acid
-
2'-methyl-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl][1,1'-biphenyl]-2-carboxamide
-
2'-[(aminooxy)carbonyl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl][1,1'-biphenyl]-2-carboxamide
-
2-(4-[[4-(1-ethoxyethenyl)piperidin-1-yl]methyl]-1H-1,2,3-triazol-1-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-(4-[[4-(propan-2-yl)piperazin-1-yl]methyl]-1H-1,2,3-triazol-1-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethyl [1,1'-biphenyl]-2-ylcarbamate
-
2-(4-[[bis(2-hydroxyethyl)amino]methyl]-1H-1,2,3-triazol-1-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-(pyridin-3-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-bromo-N-[2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethyl]benzene-1-sulfonamide
-
2-[4-[(4-chlorophenyl)sulfamoyl]phenoxy]-N-(pyridin-3-ylmethyl)acetamide
-
2-[4-[(4-hydroxypiperidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-[4-[(4-methylpiperazin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
inhibitor of the extracellular enzyme form
2-[4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-[4-[(morpholin-4-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-[4-[(piperidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
3-(1-(4-(2-([1,1'-biphenyl]-2-yloxy)ethyl)benzyl)-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-(6-([1,1'-biphenyl]-2-yloxy)hexyl)-1H-1,2,3-triazol-4-yl)-pyridine
-
3-(1-(7-(4-([1,1'-biphenyl]-2-yl)-1H-1,2,3-triazol-1-yl)-heptyl)-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-(7-([1,1'-biphenyl]-2-yloxy)heptyl)-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-(8-([1,1'-biphenyl]-2-yloxy)octyl)-1H-1,2,3-triazol-4-yl)-pyridine
-
3-(1-[6-[(2'-methyl[1,1'-biphenyl]-2-yl)oxy]hexyl]-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-[6-[([1,1'-biphenyl]-2-yl)oxy]hexyl]-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-[7-[([1,1'-biphenyl]-2-yl)oxy]heptyl]-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-[7-[4-([1,1'-biphenyl]-2-yl)-1H-1,2,3-triazol-1-yl]heptyl]-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-[8-[([1,1'-biphenyl]-2-yl)oxy]octyl]-1H-1,2,3-triazol-4-yl)pyridine
-
3-[1-[(4-[2-[([1,1'-biphenyl]-2-yl)oxy]ethyl]phenyl)methyl]-1H-1,2,3-triazol-4-yl]pyridine
-
4-chloro-N-[(5-[[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]sulfamoyl]thiophen-2-yl)methyl]benzamide
-
-
4-chloro-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
4-[([7-chloro-3-methyl-2-[(4-methylpiperazin-1-yl)methyl]-4-oxo-3,4-dihydroquinazolin-6-yl]methyl)(prop-2-yn-1-yl)amino]-N-[(pyridin-3-yl)methyl]benzamide
-
4-[[(2E)-3-(pyridin-3-yl)prop-2-enoyl]amino]-N-(2,2,2-trifluoroethyl)benzamide
-
4-[[(3,7-dimethyl-4-oxo-3,4-dihydro-1,2,3-benzotriazin-6-yl)methyl](3-methylbut-2-en-1-yl)amino]-N-[(pyridin-3-yl)methyl]benzamide
-
4-[[(4-tert-butylbenzene-1-sulfonyl)amino]methyl]-N-(pyridin-3-yl)benzamide
-
5,6-dimethoxy-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-(3,4-dichlorobenzyl)-4-oxo-N-(pyridin-3-ylmethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamide
-
5-(hydroxymethyl)-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-chloro-N-(4-[1-[(2S)-oxolane-2-carbonyl]piperidin-4-yl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-cyano-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-fluoro-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-fluoro-N-[4-[1-(1-methylpiperidine-4-carbonyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-fluoro-N-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-methoxy-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-methyl-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5P-DADMe-NMN
poor, competitive inhibitor of non-ATP and ATP coupled NMN synthesis with respect to PRPP and nicotinamide, 3-fold increased binding in presence of ATP
6-[(benzylcarbamoyl)amino]-N-cyclohexyl-N-[2-(morpholin-4-yl)ethoxy]hexane-1-sulfonamide
-
6-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]hexyl [1,1'-biphenyl]-2-ylcarbamate
-
7-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)heptyl [1,1'-biphenyl]-2-ylcarbamate
-
alpha-D-5-phosphoribosyl 1-diphosphate
inhibits ATPase activity at 1 mM concentration, nearly complete inhibition of ADP-ATP exchange at 100 microM
ethyl [(E)-[4-(piperidine-1-sulfonyl)anilino][[(pyridin-3-yl)methyl]amino]methylidene]carbamate
-
-
gallotanine
-
i.e. (2R,3S,5R,6S)-tetrahydro-2H-pyran-2,3,4,5,6-pentaylpentakis(oxycarbonyl-5,6-dihydroxybenzene-3,1-diyl) pentakis(3,4,5-trihydroxybenzoate)
N''-cyano-N-([4-[6-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl]methyl)-N'-pyridin-4-ylguanidine
-
N''-cyano-N-pyridin-4-yl-N'-([4-[3-(trifluoromethoxy)benzene-1-sulfonyl]phenyl]methyl)guanidine
-
N''-cyano-N-pyridin-4-yl-N'-([4-[3-(trifluoromethyl)benzene-1-sulfonyl]phenyl]methyl)guanidine
-
N''-cyano-N-pyridin-4-yl-N'-[[4-(quinoline-8-sulfonyl)phenyl]methyl]guanidine
-
N''-cyano-N-[[4-(3,5-difluorobenzene-1-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N''-cyano-N-[[4-(3-methoxybenzene-1-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N''-cyano-N-[[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)phenyl]methyl]-N'-pyridin-3-ylguanidine
-
N''-cyano-N-[[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N''-cyano-N-[[4-(cyclohexanesulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N''-cyano-N-[[4-(phenylmethanesulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N''-cyano-N-[[4-(pyridine-3-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N-(2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-oxoethyl)-3-methylthiophene-2-carboxamide
-
N-(2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-oxoethyl)-5-methylthiophene-2-carboxamide
-
N-(4-[1-[2-methyl-2-(4-methylpiperazin-1-yl)propanoyl]piperidin-4-yl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-[3-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]propyl]phenyl)[1,1'-biphenyl]-2-carboxamide
-
N-(4-[4-[(1H-benzimidazol-2-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(2,6-difluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(2-chlorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(2-fluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(2-methylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(3-chlorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(3-fluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(3-methylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-aminophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-bromophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-butylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-chlorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-fluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-methylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-nitrophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(furan-2-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(furan-3-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(naphthalen-2-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-[[(oxan-3-yl)methyl]carbamoyl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-[[(oxolan-3-yl)methyl]carbamoyl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-[[1-(2-methylbutanoyl)piperidin-4-yl]oxy]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-[[1-(propan-2-yl)-1H-pyrazol-4-yl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-(4-[[3-(trifluoromethoxy)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-(4-[[3-(trifluoromethyl)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
N-(4-[[4-(trifluoromethyl)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-(4-[[5-(trifluoromethyl)pyridin-3-yl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide
-
N-(7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl)[1,1'-biphenyl]-2-carboxamide
MV78
N-(8-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)octyl)biphenyl-2-sulfonamide
-
N-([1,1'-biphenyl]-2-yl)-8-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)octanamide
-
N-([1,1'-biphenyl]-2-yl)-8-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)-octanamide
-
N-([1,1'-biphenyl]-2-yl)-8-(5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl)octanamide
-
N-([4-(3,5-difluorobenzene-1-sulfonyl)phenyl]methyl)imidazo[1,2-a]pyridine-6-carboxamide
GNE-617
N-([4-[(3,5-difluorophenyl)methyl]phenyl]methyl)imidazo[1,2-a]pyridine-6-carboxamide
-
N-([4-[1-(oxan-4-yl)piperidine-4-sulfonyl]phenyl]methyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
-
N-([4-[4-(oxetan-3-yl)piperazine-1-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-([4-[4-(pyrrolidin-1-yl)piperidine-1-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-([4-[6-(dimethylamino)pyridine-3-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-([4-[6-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-biphenyl-2-yl-8-(4-pyridin-3-yl-1H-1,2,3-triazol-1-yl)octanamide
displays an IC50 for cytotoxicity in vitro of 3.8 nM and an IC50 for NAD depletion of 3.0 nM. Compound induces autophagic cell death
-
N-[(5-[[3-(trifluoromethyl)phenyl]sulfonyl]pyridin-2-yl)methyl]furo[2,3-c]pyridine-2-carboxamide
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(pyridin-3-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(pyridin-4-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(thiophen-2-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(thiophen-3-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-[4-(4-[[4-(trifluoromethoxy)phenyl]methyl]piperazine-1-sulfonyl)phenyl]thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-[4-(4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-sulfonyl)phenyl]thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-[4-[4-(pyridin-2-yl)piperazine-1-sulfonyl]phenyl]thiourea
-
-
N-[([1,1'-biphenyl]-2-yl)methyl]-2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethan-1-amine
-
N-[1,1'-biphenyl]-2-yl-N'-[2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethyl]urea
-
N-[1,1'-biphenyl]-2-yl-N'-[6-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]hexyl]urea
-
N-[1,1'-biphenyl]-2-yl-N'-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]urea
-
N-[2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethyl][1,1'-biphenyl]-2-carboxamide
-
N-[2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethyl][1,1'-biphenyl]-2-sulfonamide
-
N-[2-chloro-5-(trifluoromethyl)phenyl]-4-([[(pyridin-3-yl)methyl]carbamoyl]amino)benzene-1-sulfonamide
-
N-[3-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(1-benzoylazetidin-3-yl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(1-propyl-1H-pyrazole-3-sulfonyl)phenyl]-2-(pyridin-3-yl)cyclopropane-1-carboxamide
-
N-[4-(4-acetylpiperazine-1-sulfonyl)phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-[4-(4-benzoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(4-benzylpiperazine-1-sulfonyl)phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-[4-(4-cyclohexylpiperazine-1-sulfonyl)phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)phenyl]-N'-[(pyridin-3-yl)methyl]urea
-
N-[4-(benzenesulfonyl)phenyl]-2-(pyridin-3-yl)cyclopropane-1-carboxamide
-
N-[4-(morpholin-4-ylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-(phenylsulfonyl)benzyl]-5-(pyridin-3-yl)-1H-pyrazole-3-carboxamide
-
N-[4-(piperidin-1-ylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-(piperidin-1-ylsulfonyl)benzyl]imidazo[1,2-a]pyridine-6-carboxamide
-
N-[4-(quinolin-3-ylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-([[(3S)-oxolan-3-yl]methyl]carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(1-ethyl-1H-pyrazol-4-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(1-propyl-1H-pyrazol-4-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(3,3-dimethylbutyl)(methyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(3,3-dimethylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(3,5-difluorophenyl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
-
N-[4-[(3-methylbutyl)carbamoyl]phenyl]-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(3-methylbutyl)sulfamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(3-phenylpropyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(4-cyanopiperidin-1-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(4-hydroxypiperidin-1-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(4-methylpentanoyl)amino]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(4E)-4-(2,3-dimethoxybenzylidene)-5-oxo-4,5-dihydro-1,3-oxazol-2-yl]phenyl]thiophene-2-carboxamide
-
-
N-[4-[(5-chloropyridin-3-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(6-methylpyridin-3-yl)sulfonyl]benzyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
-
N-[4-[1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[1-(3-hydroxy-3-methylbutanoyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[1-(3-methyloxetane-3-carbonyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[1-(cyclopropanesulfonyl)piperidin-4-yl]phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[4-(4-methylphenyl)piperazine-1-sulfonyl]phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-[4-[4-(pyridin-2-yl)piperazine-1-carbonyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[5-[(3-methylbutyl)carbamoyl]pyridin-2-yl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[6-[(3-methylbutyl)carbamoyl]pyridin-3-yl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[6-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]hexyl][1,1'-biphenyl]-2-carboxamide
-
N-[7-[4-(1-oxo-1lambda(5)-pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl][1,1'-biphenyl]-2-carboxamide
-
N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]-2-(1H-1,2,3-triazol-1-yl)benzamide
inhibitor of the intracellular enzyme form
N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]-2-(1H-1,2,3-triazol-4-yl)benzamide
-
N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]-2-[4-[(pyrrolidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]benzamide
-
N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl][1,1'-biphenyl]-2-carboxamide
-
N-[8-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]octyl][1,1'-biphenyl]-2-sulfonamide
-
N-[[4-(3,5-difluorobenzene-1-sulfonyl)phenyl]methyl]imidazo[1,2-a]pyridine-6-carboxamide
-
N-[[4-(4-aminopiperidine-1-sulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[[4-(4-methoxypiperidine-1-sulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[[4-(6-methylpyridine-3-sulfonyl)phenyl]methyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
-
N-[[4-(7-oxa-2-azaspiro[3.5]nonane-2-sulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[[4-(benzenesulfonyl)phenyl]methyl]-1,1-dioxo-2H-pyrido[4,3-e][1,2,4]thiadiazin-3-amine
-
N-[[4-(benzenesulfonyl)phenyl]methyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[[4-(benzenesulfonyl)phenyl]methyl]-1H-pyrazolo[4,3-b]pyridine-5-carboxamide
-
N-[[4-(benzenesulfonyl)phenyl]methyl]-N''-cyano-N'-pyridin-3-ylguanidine
-
teglarinad
water soluble pro-drug of N-[6-(4-chlorophenoxy)hexyl]-N''-cyano-N'-phenylguanidine (CHS828)
tert-butyl 4-[4-([[(pyridin-3-yl)methyl]carbamothioyl]amino)benzene-1-sulfonyl]piperazine-1-carboxylate
-
-
tert-butyl trans-1-(2-(pyridin-3-yl)cyclopropanecarbonyl)-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate
-
tert-butyl trans-6-(2-(pyridin-3-yl)cyclopropanecarbonyl)-2,6-diazaspiro[3.4]octane-2-carboxylate
-
trans-(R,R)-N-(4-((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-(S,S)-N-(4-((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-(S,S)-N-(4-((1-propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
potent inhibitor
trans-2-(6-aminopyridin-3-yl)-N-(4-(phenylsulfonyl)benzyl)-cyclopropanecarboxamide
-
trans-2-(6-aminopyridin-3-yl)-N-(4-(phenylsulfonyl)phenyl)-cyclopropanecarboxamide
-
trans-2-(pyridin-3-yl)-N-(4-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)sulfonyl)phenyl)cyclopropanecarboxamide
-
trans-2-(pyridin-3-yl)-N-(4-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)sulfonyl)phenyl)cyclopropanecarboxamide
-
trans-2-(pyridin-3-yl)-N-(4-((3-(trifluoromethoxy)phenyl)-sulfonyl)phenyl)cyclopropanecarboxamide
-
trans-2-(pyridin-3-yl)-N-(4-((3-(trifluoromethyl)phenyl)-sulfonyl)phenyl)cyclopropanecarboxamide
-
trans-2-(pyridin-3-yl)-N-(4-((tetrahydro-2H-pyran-4-yl)-sulfonyl)phenyl)cyclopropanecarboxamide
-
trans-N-(4-((1-(2-Hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)-sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((1-ethyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((1-Isopropyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((1-isopropyl-3-methyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((1-isopropyl-5-methyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((1-propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((3,5-difluorophenyl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((3-(methylsulfonyl)phenyl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((6-methylpyridin-3-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-(1-benzoylpiperidin-4-yl)butyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
-
trans-N-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-ylsulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-(morpholinosulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
-
trans-N-(4-(phenylsulfonyl)benzyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
-
trans-N-(4-(phenylsulfonyl)benzyl)-2-(pyridin-4-yl)-cyclopropanecarboxamide
-
trans-N-(4-(phenylsulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
-
trans-N-(4-(phenylsulfonyl)phenyl)-2-(pyridin-4-yl)-cyclopropanecarboxamide
-
trans-N-(6-(4-chlorophenoxy)hexyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
-
[4-(diphenylmethyl)piperazin-1-yl][5-(pyridin-3-yl)-1H-pyrazol-3-yl]methanone
-
(2E)-3-(6-aminopyridin-3-yl)-N-((5-[4-(4,4-difluoropiperidine-1-carbonyl)phenyl]-7-(4-fluorophenyl)-1-benzofuran-2-yl)methyl)prop-2-enamide
KPT-9274
(2E)-3-(6-aminopyridin-3-yl)-N-((5-[4-(4,4-difluoropiperidine-1-carbonyl)phenyl]-7-(4-fluorophenyl)-1-benzofuran-2-yl)methyl)prop-2-enamide
KPT-9274
(2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
FK866
(2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
FK866, potent inhibitor
APO866
also known as FK866, (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridine-3-yl)-acrylamide, no impact on cell viability, dose-dependent reduction of levels of intracellular NAD in and secretion of TNFalpha, IL-1beta, IL-6 (pro-inflammatory cytokines) by monocyctes, monocyte-derived dendritic cells and total PBMCs upon stimulation of inflammatory response by 100 ng/ml lipopolysaccharide (LPS) or 5 microgram/ml Pansorbin (Staphylococcus aureus cells, SAC)
APO866
also known as FK866, (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridine-3-yl)-acrylamide, 10 mg/kg, DBA/1 mice: beneficial effects on collagen-induced arthritis (CIA) due to impaired secretion of inflammatory cytokines (reduction of the mean arthritic score and number of affected paws from mice with CIA as well as decrease in local levels of IL-1beta and IL-6 but no impact on IL-10, IFN-gamma, CCL5 and IL-12p70 levels, decrease in inflammatory infiltrate and hyperplasia in knees and paws from mice with CIA) but not due to toxicity (no premature death of individuals, no impact on histology of liver, spleen, lung, gut, kidney, inguinal lymph nodes and brain, normal liver alanine aminotransferase levels, no enhanced apoptosis in arthritic paws) and not due to impact on anti-collagen immune response (similar anti-collagen IgG levels); also known as FK866, (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridine-3-yl)-acrylamide, 10 mg/kg, isolated peritoneal exudate inflammatory cells (PEC) from C57BL/6 mice: time-dependent NAD depletion (lowest at 9 h, recovery after 14 h), addition of 10 mM NMN abolishes a reduction of intracellular NAD+ concentration as well as TNFalpha and IL-6 secretion (pro-inflammatory cytokines) in PECs induced by in vivo or in vitro stimulation of inflammatory response with 5 microgram/ml Pansorbin (Staphylococcus aureus cells, SAC) or 100 ng/ml lipopolysaccharide (LPS)
FK-866
i.e. (2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-phenylprop-2-enamide
FK-866
the nicotinamide-binding site is important for inhibition by FK-866
FK866
-
a highly specific noncompetitive inhibitor the enzyme, represents a novel mechanism for induction of tumor cell apoptosis, counteracted by nicotinic acid and nicotinamide
FK866
Nampt antagonist, 10 nM, reduction of Nampt activity in SMCs to 22 +/-2% of baseline activity accompanied with shortened senescent-free survival; reducing Nampt activity with the antagonist FK866 induces premature senescence in smooth muscle cells
FK866
FK866 is bound in a tunnel at the interface of the NMPRTase dimer, the inhibitor can reduce cellular NAD+ levels and induce apoptosis in tumors
FK866
i.e. daporinad, (E)-N-[4-[1-(benzoyl)piperidin-4-yl]butyl]-3-pyridin-3-ylprop-2-enamide
FK866
i.e. (E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
FK866
FK866 is bound in a tunnel at the interface of the NMPRTase dimer, the inhibitor can reduce cellular NAD+ levels and induce apoptosis in tumors
GMX-1778
i.e. (E)-1-(6-(4-chlorophenoxy)hexyl)-2-cyano-3-(pyridin-4-yl)-guanidine
GMX1777
-
i.e. 1-[2-(2-(2-(2-methoxyethoxy)-ethoxy)ethoxy)-ethoxy-carbonyloxymethyl]-4-[N'-cyano-N''-(6-(4-chlorophenyl)-hexyl)-N-guanidino]pyridinium chloride, prodrug of GMX1778. A dose of 75 mg/kg administered over a 24 h intravenous infusion causes tumor regression in the IM-9 model, the SHP-77 model, and HCT-116 model. A 72 h continuous intravenous infusion is also effective in the IM-9 model, but is associated with smaller therapeutic index
GMX1777
-
i.e. 1-[2-(2-(2-(2-methoxyethoxy)-ethoxy)ethoxy)-ethoxy-carbonyloxymethyl]-4-[N'-cyano-N''-(6-(4-chlorophenyl)-hexyl)-N-guanidino]pyridinium chloride, prodrug of GMX1778. A dose of 75 mg/kg administered over a 24 h intravenous infusion produces GMX1778 steady-state plasma levels of about 1 microg/ml and causes nicotinamide dinucleotide levels to decrease significnantly in tumors. Nicotinic acid protects mice treated with a lethal dose of GMX1777
N-(4-[[3-(trifluoromethyl)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-(4-[[3-(trifluoromethyl)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
-
N-(4-[[3-(trifluoromethyl)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-([1,1'-biphenyl]-2-yl)-8-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]octanamide
-
N-([1,1'-biphenyl]-2-yl)-8-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]octanamide
GPP78
N-([1,1'-biphenyl]-2-yl)-8-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]octanamide
GPP78
N-[(5-[[3-(trifluoromethyl)phenyl]sulfonyl]pyridin-2-yl)methyl]furo[2,3-c]pyridine-2-carboxamide
-
N-[(5-[[3-(trifluoromethyl)phenyl]sulfonyl]pyridin-2-yl)methyl]furo[2,3-c]pyridine-2-carboxamide
-
N-[4-[(3,5-difluorophenyl)sulfonyl]benzyl]imidazo[1,2-a]pyridine-6-carboxamide
-
N-[4-[(3,5-difluorophenyl)sulfonyl]benzyl]imidazo[1,2-a]pyridine-6-carboxamide
-
-
N-[4-[(3,5-difluorophenyl)sulfonyl]benzyl]imidazo[1,2-a]pyridine-6-carboxamide
-
N-[6-(4-chlorophenoxy)hexyl]-N''-cyano-N'-phenylguanidine
CHS828, potent inhibitor
NAD+
competitive inhibitor of non-ATP and ATP coupled NMN synthesis with respect to PRPP and nicotinamide
NAD+
-
1 mM, 50%-90% inhibition in various tissues, at 0.2 mM not inhibitory in lung and liver; strong (thigh muscle)
NADH
competitive inhibitor of non-ATP and ATP coupled NMN synthesis with respect to PRPP and nicotinamide
additional information
no impact on ADP-ATP exchange rate by 10 microM adenylate kinase inhibitor P(1), P(5)-di(adenosine-5-)pentaphosphate (Ap5A), NAMPT does not accommodate Ap5A
-
additional information
-
no impact on ADP-ATP exchange rate by 10 microM adenylate kinase inhibitor P(1), P(5)-di(adenosine-5-)pentaphosphate (Ap5A), NAMPT does not accommodate Ap5A
-
